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Abstract: Among mediators of inflammation, chemokines play a pivotal role in the neuroinflammatory
process related to Alzheimer’s disease (AD). The chemokine Bv8/prokineticin 2 (PROK2) is a
critical player in inflammatory and neuroinflammatory diseases and has been demonstrated to
be involved in Aβ toxicity. The aim of the present study was to extend the research to rats
chronically intracerebroventricularly (i.c.v.) injected with Aβ, to an AD transgenic mouse model, and
subsequently to AD patients, mainly with the aim of detecting a potential biomarker. Real-time PCR
and immunofluorescence analysis were used to evaluate Prokineticin-2 (PROK2) mRNA and the
corresponding protein levels in both animal and human AD brain extracts, and the ELISA test was
used to measure the amount of PROK2 in the serum of AD patients. We demonstrated a significant
upregulation of PROK2 levels in brain tissues of Aβ1–42 i.c.v. injected rats, transgenic AD mice
(Tg2576), and in the hippocampus of AD patients. Additionally, through a pilot study, an approximate
twofold increase of PROK2 levels has been proved in the serum of AD patients, compared to the
control subjects, identifying a potential blood-based biomarker of the disease.
Keywords: Alzheimer’s disease; neuroinflammation; chemokines; prokineticins; blood biomarkers
1. Introduction
Alzheimer’s disease (AD) is the widespread neurodegenerative disease, mainly characterized
by the extracellular deposition of misfolded amyloid beta (Aβ) proteins in amyloid plaques and by
intraneuronal tangles composed by the hyperphosphorylated tau protein [1].
Over the past few decades, a role played by the immune system in AD has been highlighted,
as demonstrated by the presence of activated microglia and astrocytes in the brains of affected
patients [2,3]. Indeed, deposition of aberrant proteins is responsible for an immune reaction against
Cells 2019, 8, 1430; doi:10.3390/cells8111430 www.mdpi.com/journal/cells
Cells 2019, 8, 1430 2 of 13
proteins that trigger a neuroinflammatory response [4]. Neuroinflammation in AD is present at both a
parenchymal level and at the barriers of the brain, increasing with the ongoing deposition of Aβ and
the disease progression [3].
However, correlative analyses of the clinical symptoms that precede AD, namely mild cognitive
impairment (MCI), and the presence of inflammatory mediators in the cerebrospinal fluid (CSF) have
indicated a much earlier involvement of the immune system [5,6].
Among mediators of inflammation, chemokines play a pivotal role in the neuroinflammatory
process due to their dual function as both chemoattractants for immune cells and molecular messengers
in crosstalk among central nervous system (CNS)-resident cells. In fact, it has been demonstrated
that chemokines play a critical role in the onset and progression of neuroinflammation, by affecting
the functions of various cell populations, including resident glial cells, and by infiltrating immune
cells [7–9].
Recent data suggest that among pro-inflammatory signal molecules released by astrocytes and
microglia in AD pathology, the chemokine system (chemokine ligands and their cognate receptors)
participates in the immune response in AD brain [8,10].
Chemokines are small heparin-binding proteins (8–14 kDa), primarily known for their role in the
attraction of circulating leukocytes to sites of inflammation or injury during immune responses [11].
There are data suggesting that some chemokines may represent promising biomarkers of AD, since
their levels appeared significantly modified in the blood or CSF of AD patients.
Included in the chemokines family, elevated CX3CL1 (fractalkine) plasma levels have been found
in mild cognitive impairment (MCI) and mild AD patients [12], as well as an increase of CX3CL1 gene
expression in the brains of AD patients in respect to control subjects, mainly in the early stage [13].
Moreover, changes in the expression of chemokine receptors on peripheral blood cells of AD
patients have also been reported, suggesting an influence of the pro-inflammatory milieu in AD [14,15].
Furthermore, a very recent international multicentric study, analyzing 53 inflammatory proteins
in plasma of both AD and MCI, identified eotaxin-1 (higher in AD plasma vs. CTRL and MCI) and
Monocyte Chemoattractant Protein-1 (MCP-1 or CCL2) (lower in AD plasma vs. CTRL and MCI),
as potential inflammatory AD biomarkers [16].
These data support the importance of such small proteins, mediators of neuroinflammation, as a
tool for supporting AD diagnosis and to better differentiate patients from healthy controls.
A family of chemokines, Bv8/prokineticin (PROK2), interacting with two G-protein coupled
receptors (PKR1 and PKR2), has recently emerged as a critical player in immune system and
inflammatory diseases [17,18].
It has been demonstrated that PROK2 expression is upregulated by several pathological stressors,
including hypoxia and reactive oxygen species. It has also been shown that PROK2 is an insult-inducible
endangering mediator for cerebral ischemic injury, supporting a role of this chemokine in brain
pathological states [19,20].
More recently, our team established that Aβ, both in vitro, in neuron and astrocyte primary
cultures, and in vivo, in intracerebroventricularly (i.c.v.) injected rats, was able to upregulate the
prokineticin system early on, indicating a well-defined involvement of PROK2 in Aβ toxicity. Moreover,
we demonstrated that the pharmacological blockade of the prokineticin system can exert neuroprotective
effects by preventing PROK2 upregulation, thus suggesting that this system may represent, at least in
animal models, a new pathological hallmark for AD [21–23].
Considering the involvement of PROK2 and its receptors in Aβ toxicity, the present study aimed
to extend our research to rats chronically i.c.v. injected with Aβ, to the AD transgenic mouse model
Tg2576, and subsequently to AD patients, mainly with the aim of detecting a potential biomarker.
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2. Materials and Methods
2.1. Chemicals
Aβ1–42 (Abcam, Cambridge, UK) was dissolved in sterile phosphate buffer (PBS; 0.01 M NaH2PO4,
0.15 M NaCl, pH 7.4) at a concentration of 1 mg/mL and stored at −20 ◦C. Before in vivo injection,
aliquots of Aβ peptide were aggregated by incubation at 37 ◦C for 72 h [24].
Human brain material was provided via the rapid autopsy program of the Netherlands
Brain Bank (NBB), which provides post-mortem specimens from clinically well documented and
neuropathologically confirmed cases.
2.2. Animals
Ethics statement: The experiments which involved animal care and treatment were performed in
accordance with the guidelines of the European Communities Council (2010/63/UE) and the protocol
was approved by the Animal Care and Use Committee of the Italian Ministry of Health (authorization
number: 79/2015-PR).
Experiments were conducted on adult male Sprague–Dawley rats supplied by Charles River
(Charles River, Como, Italy) weighting at the time of surgery 280–320 g, and on transgenic AD mouse
line TG2576 and their non-transgenic littermates (Taconic Europe, Lille Skensved, Denmark). Animals
were group housed under 12:12 h light/dark cycles, 21 ± 2 ◦C temperature and 50–60% humidity,
with access to food and water ad libitum.
2.3. Surgery and Aβ1–42 Administration
Anesthetized rats (n = 30 rat) (ketamine–xylazine, 60 + 10 mg/kg intraperitoneally, i.p.) were
placed in a stereotaxic surgery apparatus and implanted with a plastic guide cannula (Linca, Tel-Aviv,
Israel), inserted into the left lateral ventricle through a hole drilled over the skull at the following
coordinates: antero-posterior, −1 mm; lateral, +1.8 mm relative to bregma, according to the atlas of
Paxinos and Watson [25]. The cannula was secured to the skull bone with dental cement. One week
after the implantation, rats were randomly assigned to two groups and i.c.v. injected with Aβ1–42
(1 µg/µL; 5 µL injection volume) or its vehicle (PBS; 5 µL injection volume). A 10 µL Hamilton syringe
fitted with a 26-gauge needle was used for the injection. The syringe was inserted through the guide
cannula to a depth of 4.2 mm below the external surface of the skull and at the end of the injection the
needle was left in place for 10 s to avoid reflux of the solute.
2.4. RNA Extraction and Real-Time PCR
Total RNA was isolated from homogenized prefrontal cortex and hippocampal samples using the
Trizol reagent (Sigma Aldrich, St. Louis, MO, USA) following manufacturer’s instruction. The RNA
concentration was determined by spectrophotometry and the sample’s purity was evaluated according
to 260/280 nm ratio. One microgram of total mRNA was reverse transcripted (Reverse Transcriptase,
Promega, Madison, WI, USA) to obtain cDNA, which was further used as a template in real-time
PCR (iCycler; Bio-Rad, Hercules, CA, USA). All reactions were performed in triplicate using iQ SYBR
Green Supermix (Bio-line, London, UK), under the following conditions: 95 ◦C for 10 min (polymerase
activation) followed by 40 cycles at 95 ◦C for 30 s, 56–50 ◦C (temp. depends on the Tm of primers)
for 30 s and 72 ◦C for 30 s. A reaction mixture without cDNA was used as control. The results were
quantified using the comparative threshold method. The Ct value of the specific gene of interest was
normalized to the Ct value of the endogenous control, glyceraldehydes-3-phosphate dehydrogenase
(GAPDH) for mouse and rat samples, and β-actin for human samples. The comparative Ct method
(2-∆∆Ct) was then applied using control as the reference samples. The primer sequences were reported
in Table 1.
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Table 1. Gene primary sequence.
Species Gene Sequence
Rat
GAPDH Fw: 5′-GCG AGA TCC CGC TAA CAT CAA ATG G-3′
Rev: 5′-GCC ATC CAC AGT CTT CTG AGT GGC-3′
PROK2 Fw: 5’-TCA TCA CCG GGG CTT GCG-3’
Rev: 5’-TAA CTT TCC GAG TCA GGG-3’
Mouse
GAPDH Fw: 5′-GCC AAG GCT GTG GGC AAG GT-3′
Rev: 5′-TCT CCA GGC GGC ACG TCA GA-3′
PROK2 Fw: 5′-CTC GGA AAG TTC CAT TTT GG-3′
Rev: 5′-TTC CGG GCC AAG CAA ATA AAC C-3′
Human
β-actin Fw: 5′-AGA TGA CCC AGA TCA TGT TTG-3′
Rev: 5′-TAG ATG GGC ACA GTG TGG-3′
PROK2 Fw: 5′-ATG TGC TGT GCT GTC AGT AT-3′
Rev: 5′-AAA ATG GAA CTT TAC GAG TCA-3′
2.5. Immunofluorescence
Immunofluorescence staining was performed as previously described [23]. Brains were removed
from intracardially perfused rats (PBS followed by 4% paraformaldehyde, PFA), post-fixed for 24 h in
the same fixative at 4 ◦C and cryoprotected in 30% sucrose solution at 4 ◦C until they sank. Thereafter,
brains were serially cut using a cryostat (Leica Microsystems Nussloch GmbH, Heidelberger, Germany)
to obtain coronal sections (40 µm).
After the block of non-specific sites with 3% normal donkey serum for 1 h at room temperature
(RT) the brain sections were incubated at 4 ◦C for 48 h with the following primary antibodies: rabbit
polyclonal anti-PROK2 (1/200, Abcam, Cambridge, UK, ab76747), mouse monoclonal anti-neuronal
nuclei (1/500, NeuN, MAB-90228, Immunological Sciences, Rome, Italy), mouse monoclonal anti-glial
fibrillary acidic protein (1/400, GFAP, MAB-12029, Immunological Sciences, Rome, Italy). Thereafter,
sections were washed and incubated for 2 h at RT with anti-species IgG secondary antibodies coupled
to Alexa Fluor®-488 or -555 (1:200, Immunological Sciences). The immunostaining specificity of
the secondary antibodies was detected by incubating control sections with the secondary antibodies
alone. DAPI (4′,6-diamino-2-phenylindole, 1/500, Sigma Aldrich) was used to stain the nuclei.
The immunofluorescence images were acquired with a confocal laser scanning microscope (Leica SP5,
Leica Microsystems, Wetzlar, Germany) by an experimenter who was blind to the experimental design.
The acquisition settings were maintained identical among the different experimental cases.
For figure production, brightness and contrast of images were adjusted by applying the same values,
and by taking care to leave a tissue fluorescence background for visual appreciation of the whole
fluorescence intensity features and to help comparison between the different experimental groups.
Final figures were assembled using Adobe Photoshop 7 and Adobe Illustrator 10.
2.6. In Vivo Blood Assay
A total of 40 subjects, grouped in AD (n = 20) and controls (CTRL n = 20), were recruited at the
Neurology Unit of Tor Vergata University Hospital, Rome, Italy, between 2016 and 2017.
AD was diagnosed according to 2011 criteria [26]. All of the AD patients underwent
standard diagnostic work-up for dementia, including medical examination, laboratory tests,
electroencephalogram (EEG), neuropsychological tests, brain Magnetic Resonance Imaging (MRI),
Positron Emission Tomography with 2-deoxy-2-[fluorine-18]fluoro-d-glucose integrated with
Computed Tomography, [18F] FDG PET, and lumbar puncture (LP) for CSF analysis. According
to previous works, CSF biomarkers Aβ1–42, p-tau, and total tau were used to improve diagnostic
accuracy [27]. Patients showing abnormal CSF cell count (>4 cells/µL), acute and/or chronic systemic
conditions, other neurological diseases were excluded from the study. Control subjects were age/sex
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matched healthy individuals, enrolled among non-blood relatives of AD or volunteers, which did not
have family/medical history and signs of neurological diseases.
Enrolled subjects underwent venous blood sampling. Specimens were collected in standardized
conditions, in the morning, after overnight fasting. Procedure was conducted in a comfortable room,
after the signature of informed consent. Immediately after collection, serum was aliquoted and stored
at −80 ◦C.
2.7. ELISA
Serum PROK2 levels from AD patients (age 80 ± 2) and control subjects (age 76 ± 4) were
assayed using a competitive commercial ELISA kit (Life Span BioSciences, Inc., Seattle, WA, USA)
according to the manufacturer’s instructions. The ELISA test was performed on 96-well microplates by
experimenters who were blind to the experimental design. Each sample was run in triplicate with <5%
intra-assay and <9% interassay coefficients of variation, expressing results as pg/mL.
2.8. Data Analysis
Statistical analysis was performed using SPSS 11.0.0 for Windows (SPSS Inc., Chicago, IL, USA) or
GraphPad Prism 6. All results are expressed as mean ± SEM, with n as the number of independent
samples. The significance was performed by one-way analysis of variance (ANOVA) followed by
Bonferroni’s test for multiple comparisons or by Student T test. The significance level was set at
p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***).
3. Results
3.1. Upregulation of PROK2 mRNA in Rat Brain Following Aβ Insult
We have previously demonstrated that i.c.v. injection of Aβ1–42 induced a significant increase in
PROK2 mRNA levels in rat cortex and hippocampus at early time points (6–48 h after injection) [21].
Here, we investigated the long-term modulation of PROK2 expression induced by Aβ1–42 injection
analyzing mRNA levels of PROK2 after 1, 7, 14, and 35 days in extracts of cortex and hippocampus of
treated rats. Time-course analysis of mRNA expression displayed a remarkable modulation of PROK2
in both cortex and hippocampus of Aβ1–42 injected rats. As shown in Figure 1, PROK2 mRNA levels
were significantly increased starting from day 7 after i.c.v. injection and remained at the same level up
to 35 days later, thus indicating a long-lasting effect of Aβ in the prokineticin system modulation.
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Figure 1. mRNA expression level of BV8/prokineticin (PROK2) in rat cortex and hippocampus. Relative
PROK2 mRNA expression levels were determined by qRT-PCR in cortex (A) and hippocampus (B) of
vehicle and Aβ1–42 injected rats at different time points: 1, 7, 14, 35 days after injection. The mRNA
expression levels were expressed in relation to glyceralde-hydes-3-phosphate dehydrogenase (GAPDH)
and presented as fold of increase r spect to sham rats. Data represent means ± SEM of three separate
experiments. Statistical analyses were performed using one-way ANOVA test followed by Bonferroni’s
post hoc test. ** p < 0.01; *** p < 0.001; Aβ1–42 intracerebroventricularly (i.c.v.) vs. Veh i.c.v.
3.2. Localization of PROK2 Protein in Rat Brain Following Aβ Insult
As previously established by immunofluorescence in primary mixed cortical cultures, Aβ1–42
treatment time-dependently induced upregulation of PROK2 both in body neurons (NeuN+ cells) and
in astrocytes processes (GFAP+ cells) [21]. Here, we investigated the localization of PROK2 protein in
cortex and hippocampus of rats 35 days after Aβ1–42 or vehicle injection. As shown in Figure 2, PROK2
immunofluorescence signal (green) appeared almost undetectable in the cortex and hippocampus of
vehicle infused rats, while Aβ1–42 i.c.v. injection strongly increased PROK2 expression in neurons and
astrocytes, as demonstrated by the co-localization with NeuN and GFAP, respectively. By contrast,
we did not observe any increase in PROK2 immunoreactivity in microglia (data not shown).
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Representative conf cal images of rat cortex ( ,B) and hippocampus (C,D) stained with anti-PROK2
antibody (green) 35 days after Vehicle or Aβ1–42 i.c.v. injection. Neurons were stained with NeuN
(red), astrocytes with glial fibrillary acidic protein (GFAP) (red) and cell nuclei were stained with
DAPI (blue). PROK2 immunofluorescence signal was undetectable in the cortex (A,B, first row)
and hippocampus (C,D, first row) of vehicle infused rats. Aβ1–42 i.c.v. injection strongly increased
PROK2 immunofluorescence signal in neurons and astrocytes, in both cortex and hippocampus,
as demonstrated by the colocalization with NeuN (arrow, A,C, second row) and GFAP (arrow, B,D,
second row). Scale bar, 30 µm.
3.3. Upregulation of PROK2 in Tg2576 Brain
We analyzed, by qRT-PCR, PROK2 mRNA levels in cortical and hippocampal tissues from
transgenic AD animals (Tg2576 mice, TG) at different ages (1.5, 6, and 20 months), co paring
them to wild-type (WT) control mice. As shown in Figure 3A, in cortical tissues of six-month-old
animals (pre-symptomatic stage) and at 20 mo ths a significant PROK2 upregulation was detected,
thus confirming results obtained in the non-transgenic AD animal model (Aβ i.c.v. injected rats).
Of note, the increase in PROK2 mRNA amount appeared higher in the pre-symptomatic stage, i.e.,
in six-month-old mice (2.9 ± 0.3 fold with respect to their non-transgenic CTRL) and lower in the
more advanced stage of the pathology, i.e., in 20-month-old mice (1.75 ± 0.05 fold with respect to their
non-transgenic CTRL). Moreover, in the hippocampus a PROK2 increase was observed, in both six-
and 20-month-old mice, even if this increase was not statistically significant (Figure 3B).
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3.4. Upregulation of PROK2 in AD Patients’ Brain
Subsequently, we have extended our observations to AD human brain by qRT-PCR analysis
of post-mortem hippocampal tissues obtained by the Netherlands Brain Bank (NBB). As shown in
Figure 4, a significant PROK2 mRNA upregulation (of about six times) was observed in hippocampal
regions from AD patients, as compared to age-matched cognitively intact human controls.
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Figure 4. mRNA expression level of PROK2 in hu an hippoca pus. Relative PROK2 R A
expression in hippocampus from control subjects (without neurologic and/or neurodegenerative and/or
inflammatory disease) and in patients with diagnosed Alzheimer’s disease (AD) (with overt clinical
and cognitive decline) (n = 4; ** p < 0.01 by Student T test).
3.5. Increase of PROK2 in AD Patients’ Serum
Analyzing PROK2 in the serum of 20 AD patients and 20 control subjects we found a significant
PROK2 increase in patients. As shown in Figure 5, quantitative analysis revealed an about 1.6-fold
increase of this chemokine level in serum samples obtained from AD patients, compared to samples
from control subjects (p < 0.001).
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4. Discussion
Chronic neuroinflammation in AD is accompanied by persistent activation of astrocytes
and microgl al cells and by he release of inflammatory m diators, including cytokines and
chemokines [9,28–30], whose l vel is altered in the brain, CSF, and blood of AD patients [31–33].
Specifically, ch mokines, whose primary role is regulation and enrollment of leukocytes to the
site of inflammation, represent a very important cla s of inflammatory mediators involved in AD
pathophysiology [34].
PROK2 has been demonstrated to be involved early in Aβ toxicity both in vitro, in rat cortical
primary cultures and in vivo, in rat i.c.v. infused with Aβ, indicating hat modulation of the prokinetic n
syste could be a wide-ra ging reaction to Aβ j ry, at least in acute d mage conditions [21,23].
Her , we demonstrated that PROK2 mRNA was significantly upregulated in both the prefront l
cortex and the hippocampus of Aβ1-42 injected rats, a widely used AD non-transgenic animal model,
remaining at the sa e level up to 35 days after the infusion. This therefore indicates a long- erm activity
of Aβ toxic effect in PK system modulatio . From immunofluoresc nce analysis, the increase in PROK2
immunoreactivity in respons to Aβ insult has been established in both neur ns and astrocytes, thus
confirming that astrocyt s are the main neural cells producing chemokines in response to Aβ [35–37].
Likewise, upregulation of PROK2 mRNA has been furt er observed in brain extrac s from Tg2576
(TG) mice, a reliable transgenic model of AD, at both e rly and late stages, showing the greater
significant PROK2 mRNA rise in in the cortex of pre-symptomatic stage mice. A rise in PROK2
content was also evident in hippocampal tissues from Tg2576 mice, although this was highly variable.
Furthermore, in the hippocampus of adult Tg2576 mice, a deleterious role of PROK2 has b en previously
established i long-term potentiation (LTP) experiments, as revealed by the recovery of synaptic
plasticity impairment obtained with the harmacological blockade of prokineticin receptors [21]. These
results indicate a detrime tal role of this chem kine in memory processes, sugge ting that targeting
PROK2 receptors may offer innovative potential ch nces for treatm nt of AD, at least in animal models.
In view of the increased expression of PROK2 n AD transgenic mice, we extended our research to
the human brain. This is the first observ tion describing the direct involvement of the PK system in
Alzheimer’s disease, as demonstrated by he significant rise f PROK2 mRNA in the hippocampus of
AD patients compared to age-matched, cognitively intact controls.
Interestingly, through a pilot study, we ound a substan ial increase of PROK2 l vels in the serum
of subjects affected by t pat ology, which correlates w th t e rise here describ d in post-mortem
brain tissues of AD p tients.
These preliminary data sug st that such remote pathologi al events occurring at brain level could
be also tracked in peripheral fluids of patients, opening the way for dedicated confirmatory studies.
In fact, numerous studies suggested neuroinflammation as a key pathway in AD, as plasma and
brain l vels of inflammatory prote ns were reported to grow even before clinical onset of this pathology,
generally with an inverse correlation in respect to AD progression [38,39].
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An enhancement of MCP-1 (CCL2) concentration levels has been reported in CSF and serum of
patients in the early stage of AD (MCI or mild AD) whereas, in the late stage, its amount is decreased
in the serum but remains elevated in the CSF [40–43]. Likewise, CXCL8 (interleukin 8) has been found
to be increased in both the serum and CSF of AD patients [40,44], as well as CXCL10 (IP-10), whose
levels in CSF correlated with AD cognitive impairment [41].
A very recent multicentric study has indicated that numerous plasma proteins related to
neuroinflammation, including three chemokines (eotaxin-1, MCP-1, and Macrophage Inflammatory
Proteins (MIP) 1b (MIP-1b) and complement dysregulated proteins, could significantly and
independently concur to differentiate MCI and AD patients from healthy controls. Results from
this international study, involving a great number of subjects, indicated that both the chemokines
eotaxin-1 and MCP-1 could be considered potential plasma biomarkers of the disease [16]
The results are in accordance with previous studies reporting that elevated MCP-1 and eotaxin-1
plasma levels are associated with a higher memory impairment in individuals with MCI and AD
dementia, this damaging relationship being strongest when both inflammatory markers are raised [45].
However, results shown by Morgan and collaborators demonstrated that the absolute values of
eotaxin-1 and MCP-1 plasma levels did not have significant differences, but could be considered AD
pathological markers only by a logistic regression analysis which combines their values with age and
apolipoprotein E (APOE) status.
Of note, unlike MCP-1 and eotaxin-1, whose plasma levels are only moderately altered in AD
patients, results from our work showed an increase of about 1.6 times of PROK2 level in AD plasma in
respect to controls. The results seem promising, although they require further validation in a more
consistent number of patients.
Clearly, it will be very interesting to extend the study to MCI patients to conceivably identify
a potential early disease biomarker, before the onset of significant cognitive change that may help,
together with other altered parameters, to sub-classify the pathology in individual patients, allowing
for a potential personalized treatment.
The upregulation of PROK2 in the brain of AD animal models and of patients and the crucial
increase of its levels in the serum of AD patients could identify PROK2 as a potential blood-based
biomarker of this pathology.
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